Skip to main content

Month: December 2020

Virginia National Bankshares Corporation Announces Cash Dividend

CHARLOTTESVILLE, Va., Dec. 15, 2020 (GLOBE NEWSWIRE) — Virginia National Bankshares Corporation (the “Company”) (OTCQX: VABK) announced today that on December 10, 2020, its Board of Directors declared a quarterly cash dividend of $0.30 per share to be paid on January 5, 2021 to shareholders of record as of December 22, 2020. The quarterly cash dividend represents an annual yield to shareholders of approximately 4.40% based on the closing price of the Company’s common stock on December 14, 2020.About Virginia National Bankshares CorporationVirginia National Bankshares Corporation, headquartered in Charlottesville, Virginia, is the bank holding company for Virginia National Bank (the “Bank”). The Bank has four banking offices in Charlottesville and one in Winchester, and offers loan, deposit and treasury management services in Richmond,...

Continue reading

Leslie’s, Inc. to Report Fourth Quarter and Full Fiscal 2020 Financial Results on December 21, 2020

PHOENIX, Dec. 15, 2020 (GLOBE NEWSWIRE) — Leslie’s, Inc. (“Leslie’s” or “Company”; NASDAQ:LESL), the largest and most trusted direct-to-consumer brand in the U.S. pool and spa care industry, today announced that its financial results for the fourth quarter and full fiscal 2020 will be released before market open on Monday, December 21, 2020. The Company will host a conference call at 9:00 a.m. Eastern Time to discuss the financial results.Investors and analysts interested in participating in the call are invited to dial 877-407-0784 (international callers please dial 1-201-689-8560) approximately 10 minutes prior to the start of the call. A live audio webcast of the conference call will be available online at https://ir.lesliespool.com/.A recorded replay of the conference call will be available within approximately...

Continue reading

ImmuCell Announces Restructuring of its Bank Debt

PORTLAND, Maine, Dec. 15, 2020 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a restructuring of its bank debt.Today, the Company secured a $1.5 million loan from its existing lender, Gorham Savings Bank, with a seven-year term and amortization at 3.5% per annum. Approximately $624,000 of the proceeds were used to pay down the outstanding balance on its mortgage loan with Gorham Savings Bank. In connection with that pay-down, the bank released the $1.4 million in funds that had been held by the bank in a restricted collateral account since the Company’s March 2020 financing. The remaining proceeds...

Continue reading

Apex Global Brands Reports Third Quarter 2021 Financial Results

Third Quarter Fiscal 2021 Highlights versus Third Quarter Fiscal 2020:Revenues declined to $4.1 million from $4.9 millionAdjusted EBITDA increased to $1.8 million from $1.7 millionNet loss improved to $6.0 million compared to a loss of $6.8 millionSG&A expenses declined to $2.3 million from $3.2 millionSHERMAN OAKS, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) — Apex Global Brands (OTCBB: APEX), a global brand management and licensing organization that markets a portfolio of high-equity lifestyle brands it owns, creates and elevates, today reported financial results for its third quarter of Fiscal 2021, which ended October 31, 2020.“Consistent with the overall retail sector, we continued to see challenges in the third quarter,” said Henry Stupp, Chief Executive Officer of Apex Global Brands.  “The COVID-19 pandemic continues to impact...

Continue reading

4D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

EMERYVILLE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today the closing of its initial public offering of 9,660,000 shares of its common stock, including 1,260,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price of $23.00 per share. The aggregate gross proceeds of the offering were approximately $222 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Select Market on December 11, 2020 under the ticker symbol “FDMT.”Goldman Sachs & Co. LLC, BofA Securities and Evercore ISI acted as book-running managers for the offering.Registration...

Continue reading

Dr. Ana K. Stankovic, MD, PhD, Appointed to Fluidigm Board of Directors

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the appointment of Dr. Ana K. Stankovic, MD, PhD, MSPH, to the company’s Board of Directors. Dr. Stankovic is a seasoned leader with more than 30 years of research and development experience in academic, government, in vitro diagnostic and device industry settings.Dr. Stankovic is currently managing partner at Koliada Consulting, LLC, a firm focused on biotech, medical devices and in vitro diagnostics. Previously, she was Senior Vice President, World Wide Regional Medical Affairs and Global Health, for Becton, Dickinson and Company (BD). Dr. Stankovic served in senior roles at BD for more than a decade, leading...

Continue reading

CubicFarms Announces $15,000,000 Equity Financing to Support Global Growth

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) — CubicFarm Systems Corp. (“CubicFarms” or the “Company”) (TSXV:CUB) is pleased to announce that it has entered into an agreement with Raymond James Ltd. as lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a “bought deal” basis, 11,111,111 common shares (the “Common Shares”) in the capital of the Company at a price of C$0.90 per Common Share (the “Issue Price”) for aggregate gross proceeds to the Company of approximately $10,000,000 (the “Offering”).In addition, CubicFarms intends to enter into a subscription agreement with existing shareholder Harry...

Continue reading

W. Michael Shipman to Retire; Larry A. Miller to be Named North Dallas Bank & Trust Chief Executive Officer

DALLAS, Dec. 15, 2020 (GLOBE NEWSWIRE) — North Dallas Bank & Trust Co. (OTCBB: NODB) (“NDBT”) today announced that W. Michael Shipman will retire as Chairman of the Board and Chief Executive Officer on March 31, 2021. Shipman will be succeeded by NDBT’s current President, Larry A. Miller, effective April 1, 2021.  “It is fitting that during North Dallas Bank & Trust’s 60th year in business, we appoint a new leader who has Larry’s vision, strong management style and customer based focus approach to banking,” said Shipman. “Larry’s character, ability to be innovative and his proven decision-making skills will serve our bank well as NDBT begins a new decade. We are confident that under Larry’s direction and influence NDBT will continue to raise the expectations of what a bank can be.”A photo of W....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.